Provided by Tiger Trade Technology Pte. Ltd.

PTC Inc

137.61
-6.4000-4.44%
Post-market: 137.610.00000.00%19:58 EDT
Volume:1.47M
Turnover:204.29M
Market Cap:16.44B
PE:20.25
High:144.12
Open:142.84
Low:137.50
Close:144.01
52wk High:219.69
52wk Low:133.38
Shares:119.45M
Float Shares:119.32M
Volume Ratio:1.06
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.80
EPS(LYR):6.08
ROE:23.14%
ROA:11.24%
PB:4.28
PE(LYR):22.63

Loading ...

PTC to Participate in KeyBanc Emerging Technology Summit, Morgan Stanley TMT Conference, BofA Industrials Key Leaders Conference, J.P. Morgan Global TMC Conference, and Mizuho Technology Conference

Reuters
·
Feb 28

Will Cloud-Native Onshape MBD Make PTC's (PTC) Platform Central to the Product Data Workflow Narrative

Simply Wall St.
·
Feb 27

PTC Inc. Stock Underperforms Thursday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Feb 27

A Look At PTC (PTC) Valuation After SPG Company Selects FlexPLM For Cloud PLM Expansion

Simply Wall St.
·
Feb 25

PTC Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 25

Morgan Stanley Lifts Price Target on PTC Therapeutics to $92 From $90, Keeps Overweight Rating

MT Newswires Live
·
Feb 23

J.P. Morgan Keeps Their Buy Rating on PTC Therapeutics (PTCT)

TIPRANKS
·
Feb 23

Barclays Keeps Their Buy Rating on PTC Therapeutics (PTCT)

TIPRANKS
·
Feb 23

RBC Cuts Price Target on PTC Therapeutics to $82 From $87, Keeps Sector Perform Rating

MT Newswires Live
·
Feb 20

PTC Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
Feb 20

RBC Capital Keeps Their Hold Rating on PTC Therapeutics (PTCT)

TIPRANKS
·
Feb 20

Bank of America Securities Reaffirms Their Buy Rating on PTC Therapeutics (PTCT)

TIPRANKS
·
Feb 20

Sephience-Led Growth, Global Expansion, and Robust Pipeline Underpin Buy Rating on PTC Therapeutics

TIPRANKS
·
Feb 20

PTC Therapeutics: Sephience Uptake, Advancing Pipeline, and Strengthening Financials Support Buy Rating

TIPRANKS
·
Feb 20

Earnings Flash (PTCT) PTC Therapeutics Posts Q4 Loss $1.67 per Share

MT Newswires Live
·
Feb 20

PTC Therapeutics reports Q4 EPS ($1.67), consensus (41c)

TIPRANKS
·
Feb 20

PTC Therapeutics sees 2026 product revenue up 19%-36%to $700M-$800M

TIPRANKS
·
Feb 20

PTC Therapeutics Q4 EPS $(1.67) Misses $0.07 Estimate, Sales $164.677M Miss $276.665M Estimate

Benzinga
·
Feb 20

PTC India Publishes Postal Ballot Notice Advertisements Across Key Dailies

TIPRANKS
·
Feb 19

How PTC’s (PTC) New FlexPLM Win with SPG Shapes Its Intelligent PLM Investment Story

Simply Wall St.
·
Feb 19